A phase III international, multi-center, prospective, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of nitric oxide synthase inhibition with tilarginine acetate injection in patients with cardiogenic shock complicating acute myocardial infarction, or the TRIUMPH trial

Trial Profile

A phase III international, multi-center, prospective, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of nitric oxide synthase inhibition with tilarginine acetate injection in patients with cardiogenic shock complicating acute myocardial infarction, or the TRIUMPH trial

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Tilarginine (Primary)
  • Indications Cardiogenic shock; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms TRIUMPH
  • Most Recent Events

    • 28 Mar 2007 Results have been published.
    • 23 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top